Ibai Goicoechea

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4947093/publications.pdf

Version: 2024-02-01

25 papers	798 citations	687220 13 h-index	642610 23 g-index
25 all docs	25 docs citations	25 times ranked	1798 citing authors

#	Article	IF	Citations
1	New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies. International Journal of Molecular Sciences, 2016, 17, 627.	1.8	205
2	Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. Blood, 2021, 137, 49-60.	0.6	80
3	The circulating transcriptome as a source of nonâ€invasive cancer biomarkers: concepts and controversies of nonâ€coding and coding <scp>RNA</scp> in body fluids. Journal of Cellular and Molecular Medicine, 2015, 19, 2307-2323.	1.6	78
4	Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma. Blood, 2020, 136, 199-209.	0.6	76
5	Targeted nextâ€generation sequencing and nonâ€coding <scp>RNA</scp> expression analysis of clear cell papillary renal cell carcinoma suggests distinct pathological mechanisms from other renal tumour subtypes. Journal of Pathology, 2014, 232, 32-42.	2.1	51
6	Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination. Leukemia, 2020, 34, 589-603.	3.3	41
7	MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide. Molecular Cancer Therapeutics, 2015, 14, 1236-1246.	1.9	36
8	The Circulating Transcriptome as a Source of Biomarkers for Melanoma. Cancers, 2019, 11, 70.	1.7	34
9	Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma. Leukemia, 2020, 34, 3007-3018.	3.3	26
10	Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma. Blood, 2020, 135, 2375-2387.	0.6	24
11	Preneoplastic somatic mutations including MYD88 ^{L265P} in lymphoplasmacytic lymphoma. Science Advances, 2022, 8, eabl4644.	4.7	21
12	Mutational profiling can identify laryngeal dysplasia at risk of progression to invasive carcinoma. Scientific Reports, 2018, 8, 6613.	1.6	20
13	Noncoding RNA Expression and Targeted Next-Generation Sequencing Distinguish Tubulocystic Renal Cell Carcinoma (TC-RCC) from Other Renal Neoplasms. Journal of Molecular Diagnostics, 2018, 20, 34-45.	1.2	20
14	The Urinary Transcriptome as a Source of Biomarkers for Prostate Cancer. Cancers, 2020, 12, 513.	1.7	14
15	A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma. Clinical Cancer Research, 2022, 28, 2598-2609.	3.2	14
16	Characterization of herpes simplex virus 1 strains as platforms for the development of oncolytic viruses against liver cancer. Liver International, 2011, 31, 1542-1553.	1.9	12
17	Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development. Blood, 2021, 138, 1583-1589.	0.6	11
18	An N-glycosylation hotspot in immunoglobulin Îº light chains is associated with AL amyloidosis. Leukemia, 2022, 36, 2076-2085.	3.3	10

#	Article	IF	Citations
19	Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes. Blood, 2019, 134, 506-506.	0.6	6
20	Spatial intratumoural heterogeneity in the expression of GIT1 is associated with poor prognostic outcome in oestrogen receptor positive breast cancer patients with synchronous lymph node metastases. F1000Research, 2017, 6, 1606.	0.8	5
21	Aberrant Expression of MicroRNAs in B-cell Lymphomas. MicroRNA (Shariqah, United Arab Emirates), 2016, 5, 87-105.	0.6	5
22	Spatial intratumoural heterogeneity in the expression of GIT1 is associated with poor prognostic outcome in oestrogen receptor positive breast cancer patients with synchronous lymph node metastases. F1000Research, 2017, 6, 1606.	0.8	4
23	Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells. Molecular Cancer, 2014, 13, 154.	7.9	2
24	MicroRNAs as B-cell lymphoma biomarkers. Blood and Lymphatic Cancer: Targets and Therapy, 2015, , 25.	1.2	2
25	Identification of Recurrent Mutations in the microRNA-Binding Sites of B-Cell Lymphoma-Associated Genes in Follicular Lymphoma. International Journal of Molecular Sciences, 2020, 21, 8795.	1.8	1